{"id":"faster-insulin-aspart-fiasp","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_fixedAt":"2026-03-30T13:40:52.904726","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin aspart is a recombinant human insulin analog with a single amino acid substitution (proline to aspartic acid at position 28 of the B chain) that reduces self-association and accelerates absorption. Fiasp® formulation adds niacinamide and L-arginine to further enhance the speed of absorption, allowing faster onset of action compared to standard insulin aspart, resulting in improved postprandial glucose control in diabetes patients.","oneSentence":"Faster insulin aspart is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:46:15.733Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"_fixedFields":["pubmed(17)"],"trialDetails":[{"nctId":"NCT04149262","phase":"","title":"Fiasp® Versus NovoRapid® in Children With Type 1 Diabetes on MiniMed 640G Pump With Sensor","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2019-11-15","conditions":"Type 1 Diabetes","enrollment":44},{"nctId":"NCT04698018","phase":"PHASE1","title":"A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-04-20","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":23},{"nctId":"NCT04588259","phase":"PHASE3","title":"Research Study to Compare a New Medicine \"Fast-acting Insulin Aspart\" to Another Medicine \"Insulin Aspart\" in Chinese People With Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-10-09","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":331},{"nctId":"NCT03987802","phase":"","title":"An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-01-20","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":42},{"nctId":"NCT03770767","phase":"PHASE3","title":"Insulin Fiasp vs. Insulin Novorapid During Pregnancy and Laction in Women With Pre-existing Diabetes","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2019-11-11","conditions":"Diabetes Mellitus, Pregnancy Complications","enrollment":216},{"nctId":"NCT04655690","phase":"PHASE1","title":"A Study to Look at How Safe Insulin NNC0471-0119 is and How it Works in People With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-11-09","conditions":"Diabetes Mellitus, Type 1","enrollment":48},{"nctId":"NCT03268005","phase":"PHASE3","title":"Research Study Comparing a New Medicine \"Fast-acting Insulin Aspart\" to Another Already Available Medicine \"NovoRapid\"/\"NovoLog\" in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-09-19","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1264},{"nctId":"NCT04414579","phase":"PHASE4","title":"The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus","status":"UNKNOWN","sponsor":"Mountain Diabetes and Endocrine Center","startDate":"2019-03-27","conditions":"Type 1 Diabetes Mellitus","enrollment":45},{"nctId":"NCT03977727","phase":"PHASE3","title":"FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump","status":"COMPLETED","sponsor":"Texas Diabetes & Endocrinology, P.A.","startDate":"2019-06-11","conditions":"Type 1 Diabetes Mellitus","enrollment":40},{"nctId":"NCT02825251","phase":"PHASE3","title":"Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-07-06","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":472},{"nctId":"NCT03407599","phase":"PHASE1","title":"A Trial Comparing the Pharmacokinetic Properties of Fast-acting Insulin Aspart Between Children, Adolescents and Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-01-08","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":46},{"nctId":"NCT02500706","phase":"PHASE3","title":"Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-05-04","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":1108},{"nctId":"NCT02670915","phase":"PHASE3","title":"Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-05-04","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":834},{"nctId":"NCT01934712","phase":"PHASE1","title":"A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-08-30","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":50},{"nctId":"NCT02003677","phase":"PHASE1","title":"A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-11-29","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":67},{"nctId":"NCT03212950","phase":"NA","title":"Closed-Loop With Faster Aspart in Young Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Ljubljana, Faculty of Medicine","startDate":"2017-07-10","conditions":"Type 1 Diabetes Mellitus","enrollment":20},{"nctId":"NCT02035371","phase":"PHASE1","title":"A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-01-13","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":41},{"nctId":"NCT02033239","phase":"PHASE1","title":"A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-01","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":46},{"nctId":"NCT02131246","phase":"PHASE1","title":"A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-05","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":33},{"nctId":"NCT01924637","phase":"PHASE1","title":"A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-08","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":36},{"nctId":"NCT01682902","phase":"PHASE1","title":"A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-09","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":43},{"nctId":"NCT01992588","phase":"PHASE1","title":"A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-11","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"recentPublications":[{"date":"2026 Jan","pmid":"40719607","title":"A Pilot Study Evaluating Meal Timing, Macronutrient Composition, and Faster-Acting Insulin Aspart Versus Insulin Aspart on Postprandial Glycemia with the Medtronic Advanced Hybrid Closed-Loop System.","journal":"Diabetes technology & therapeutics"},{"date":"2025 Sep","pmid":"40445776","title":"Fully Closed-Loop Improves Glycemic Control Compared with Pump with CGM in Adolescents with Type 1 Diabetes and HbA1c Above Target: A Two-Center, Randomized Crossover Study.","journal":"Diabetes technology & therapeutics"},{"date":"2025 Jun","pmid":"40129237","title":"Faster-acting insulin aspart versus insulin aspart for adults with type 1 diabetes treated with non-automated insulin pump and continuous glucose monitoring-A double-blind randomized controlled crossover trial.","journal":"Diabetes, obesity & metabolism"},{"date":"2025 May","pmid":"39996365","title":"A comparison of ultra-rapid and rapid insulin in automated insulin delivery for type 1 diabetes: A systematic review and meta-analysis of randomized controlled trials.","journal":"Diabetes, obesity & metabolism"},{"date":"2024 Jul","pmid":"38315506","title":"Postprandial Glucose Excursions with Ultra-Rapid Insulin Analogs in Hybrid Closed-Loop Therapy for Adults with Type 1 Diabetes.","journal":"Diabetes technology & therapeutics"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Conventional Insulin Aspart (NovoLog®)"],"phase":"marketed","status":"active","brandName":"Faster Insulin Aspart (Fiasp®)","genericName":"Faster Insulin Aspart (Fiasp®)","companyName":"Mountain Diabetes and Endocrine Center","companyId":"mountain-diabetes-and-endocrine-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Faster insulin aspart is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}